Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Haemonetics (HAE) received FDA approval for its PerQseal® Elite vascular closure system, expanding its large-bore closure device portfolio. The system, acquired via Vivasure Medical, offers sutureless closure for arterial procedures, with clinical data showing rapid hemostasis and no major complications. The company plans to present data at the TCT Conference.
How this was made
The 30-second read
Why it matters
The clearance adds a sutureless, bioabsorbable closure option for 14‑22F procedures, with trial data showing 0% major complications and <1‑minute hemostasis.
Market read
Regulatory approval is a primary catalyst that could lift Haemonetics' stock and influence the interventional device sector.
What to watch
Reimbursement rates and payer acceptance could constrain commercial rollout.
Background
Haemonetics announced FDA clearance for its PerQseal® Elite system, following a CE Mark in Europe and a 2026 acquisition of Vivasure Medical.
Ticker impact
FDA approval of the PerQseal® Elite vascular closure system expands Haemonetics' product portfolio.
likely upside as investors price in expanded product portfolio and potential sales growth
Regulatory clearance is a material catalyst for a medical‑device company; the product targets high‑margin structural heart procedures.
Market effects
May boost the broader interventional medical device sector as competitors face new competition.
U.S. healthcare investors could see modest inflows into med‑tech stocks.
Limited to companies with large‑bore vascular closure products.
Counterpoint
If adoption is slower than expected, the approval may not translate into near‑term revenue.
Key entities
- CompanyHaemonetics Corporation
Medical technology firm (NYSE: HAE) receiving FDA approval.
- CompanyVivasure Medical Limited
Acquired by Haemonetics in Jan 2026, source of the PerQseal technology.
